diaDexus licenses prostate test to SmithKline Beecham
This article was originally published in Clinica
Executive Summary
SmithKline Beecham's clinical laboratories division (SBCL) has obtained the exclusive rights from diaDexus to use and further improve a blood test that measures stages of development of prostate cancer. The test, called PLA2, is the first product developed and licensed by diaDexus, a Santa Clara, California-based joint venture formed in 1997 by SmithKline Beecham and Incyte Pharmaceuticals (Clinica No 773, p 9).